After NRTUA vaccination, CD8+ T cells, CD19+ B cells, and CD3+ T cells increased rapidly at the inoculation site, followed by a strong Th1 immune response mediated by CD8+ T cells (Gigley et al., 2009), which shows great potential in the stimulation of synergistic anti-tumor immune response (Fox et al., 2013b). The gene discussed is CD8A; the disease is neoplasm.